Full Text View
Tabular View
No Study Results Posted
Related Studies
Bicalutamide With or Without Everolimus in Treating Patients With Recurrent or Metastatic Prostate Cancer (UCDCC#215)
This study is ongoing, but not recruiting participants.
Study NCT00814788   Information provided by University of California, Davis

First Received on December 24, 2008.   Last Updated on March 11, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Prostate Cancer
Additional conditions recognized in this trial
Adenocarcinoma
Prostatic Neoplasms
More general conditions related to this trial
Carcinoma
Genital Diseases, Male
Genital Neoplasms, Male
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Prostatic Diseases
Urogenital Neoplasms
Interventions listed in this trial
bicalutamide
Everolimus
Additional drug interventions recognized in this trial
Sirolimus
More general drug interventions related to this trial
Androgen Antagonists
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antifungal Agents
Antineoplastic Agents
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Immunologic Factors
Immunosuppressive Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
University of California, Davis
Novartis


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services